Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Receivables - Other (2017 - 2025)

Historic Receivables - Other for Regenxbio (RGNX) over the last 10 years, with Q3 2025 value amounting to $93000.0.

  • Regenxbio's Receivables - Other fell 6409.27% to $93000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $93000.0, marking a year-over-year decrease of 6409.27%. This contributed to the annual value of $239000.0 for FY2024, which is 9478.96% down from last year.
  • Regenxbio's Receivables - Other amounted to $93000.0 in Q3 2025, which was down 6409.27% from $28000.0 recorded in Q2 2025.
  • Over the past 5 years, Regenxbio's Receivables - Other peaked at $33.5 million during Q2 2022, and registered a low of $28000.0 during Q2 2025.
  • Moreover, its 5-year median value for Receivables - Other was $2.0 million (2023), whereas its average is $8.6 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first soared by 632257.14% in 2021, then plummeted by 9971.26% in 2025.
  • Over the past 5 years, Regenxbio's Receivables - Other (Quarter) stood at $1.1 million in 2021, then surged by 2416.48% to $27.0 million in 2022, then tumbled by 83.03% to $4.6 million in 2023, then tumbled by 94.79% to $239000.0 in 2024, then plummeted by 61.09% to $93000.0 in 2025.
  • Its last three reported values are $93000.0 in Q3 2025, $28000.0 for Q2 2025, and $44000.0 during Q1 2025.